91-105 of 883
Scaling Success: Hypertension Control at MPCA with the AMA MAP™ Program
Perspectives with the AMAScaling Success: Hypertension Control at MPCA with the AMA MAP™ Program
Skin Disease and Cardiovascular Risk: Uncovering a Critical Clinical Connection
On the Frontlines of PsoriasisSkin Disease and Cardiovascular Risk: Uncovering a Critical Clinical Connection
Topline Results of the CONFIDENCE Trial
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Topline Results of the CONFIDENCE Trial
The CONFIDENCE Trial: Data Insights
DataPulse: Key Clinical Trial Insights on Nonsteroidal MRAs in CKM Syndrome ManagementThe CONFIDENCE Trial: Data Insights
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Albuminuria Change and Finerenone's Effect on CV Outcomes
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Albuminuria Change and Finerenone's Effect on CV Outcomes
- advertisement
Improving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Heart MattersImproving ATTR-CM Diagnosis: Insights on Heart Failure Phenotypes
Early Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Heart MattersEarly Initiation of Acoramidis in ATTR-CM: Importance and Long-Term Impacts
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Broadcast ReplayNovel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Rivaroxaban as effective as warfarin for left ventricular thrombus post-MI
ACC Action CenterRivaroxaban as effective as warfarin for left ventricular thrombus post-MI
Mobile integrated health program in patients with HF
ACC Action CenterMobile integrated health program in patients with HF
- advertisement
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC Action CenterPhase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
AI model may accelerate risk stratification of coronary revascularization in ED
ACC Action CenterAI model may accelerate risk stratification of coronary revascularization in ED
Dapagliflozin reduces worsening HF in elderly TAVI patients
ACC Action CenterDapagliflozin reduces worsening HF in elderly TAVI patients
